Frontier Acquisition Corp. Announces Closing of $230 Million Initial Public Offering

Rhea-AI Summary

Frontier Acquisition Corp. has successfully closed its initial public offering (IPO) of 23,000,000 units at $10.00 each, raising $230,000,000 in gross proceeds. This includes the exercise of an over-allotment option by underwriters for an additional 3,000,000 units. Each unit consists of one Class A ordinary share and a quarter of a redeemable warrant, with potential to purchase shares at $11.50. The units are traded on Nasdaq under "FRONU," while Class A shares and warrants will trade under "FRON" and "FRONW." The company aims to leverage its leadership team's experience in healthcare and technology for long-term shareholder value.

Positive

• Successful IPO raised $230,000,000 in gross proceeds.
• Leadership team has extensive experience in healthcare and technology, which may enhance strategic acquisitions.

Negative

• None.

Frontier Acquisition Corp. (the “Company”), a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses, today announced that it closed its initial public offering of 23,000,000 units at a price of $10.00 per unit, which includes the exercise in full by the underwriters of their option to purchase an additional 3,000,000 units. Total gross proceeds from the offering are $230,000,000, before deducing underwriting discounts and commissions and other offering expenses. Each unit consists of one Class A ordinary share of the Company and one-fourth of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share of the Company at a price of $11.50 per share. The units are listed on the Nasdaq Capital Market under the symbol “FRONU.” Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the Nasdaq Capital Market under the symbols “FRON” and “FRONW,” respectively.

Frontier Acquisition Corp., sponsored by an affiliate of Falcon Edge Capital and Apeiron Investment Group, is led by Chief Executive Officer Christian Angermayer, Co-Presidents Rick Gerson and Ryan Khoury and Co-Chairmen of the board David A. Sinclair and Peter Attia and director Jonathan Christodoro. The Company intends to leverage its leadership team’s experiences to create significant long-term value for the Company’s shareholders. The team’s experiences include: Christian Angermayer as founder of Apeiron Investment Group, Peter Attia as a practicing physician focusing on the applied science of longevity and co-founder and chief medical officer of the fasting app Zero, and David A. Sinclair as Professor of Genetics at Harvard Medical School and co-founder of several biotechnology companies. While the Company intends to pursue opportunities at the intersection of the healthcare and technology industries, the Company will not be limited to a particular industry or geographic region in its identification and acquisition of a target company.

Credit Suisse Securities (USA) LLC and Berenberg Capital Markets LLC served as the underwriters for the offering.

The offering is being made only by means of a prospectus. Copies of the prospectus may be obtained from: Credit Suisse Securities (USA) LLC, c/o Credit Suisse Securities (USA) LLC, Attn: Prospectus Department, 6933 Louis Stephens Drive, Morrisville, North Carolina 27560, Telephone: 1-800-221-1037, Email: usa.prospectus@credit-suisse.com.

A registration statement relating to the securities became effective on March 10, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Cautionary Note Concerning Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the anticipated use of the net proceeds. No assurance can be given that the net proceeds of the offering will be used as indicated. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company's registration statement and preliminary prospectus for the Company's offering filed with the Securities and Exchange Commission (“SEC”). Copies are available on the SEC's website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210315005774/en/

FAQ

What was the gross proceeds from Frontier Acquisition Corp.'s IPO?

The gross proceeds from the IPO were $230,000,000.

What is the trading symbol for Frontier Acquisition Corp. units?

The units of Frontier Acquisition Corp. are traded on Nasdaq under the symbol 'FRONU.'

What are the expected trading symbols for the Class A ordinary shares and warrants?

Class A ordinary shares will trade under 'FRON' and warrants under 'FRONW' on Nasdaq.

Who sponsored Frontier Acquisition Corp.?

Frontier Acquisition Corp. is sponsored by affiliates of Falcon Edge Capital and Apeiron Investment Group.

What industry focus does Frontier Acquisition Corp. have?

Frontier Acquisition Corp. intends to pursue opportunities at the intersection of healthcare and technology but is not limited to any specific industry.